Podcast appearances and mentions of ursula matulonis

Editor’s Choice Paper: Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer Hosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Kathleen N. Moore, MD, GOG-F and Stephenson Cancer Center at the University of Oklahoma Health Sciences Center

Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Ann Oluloro, MD, MPH, University of Washington Eloise Chapman-Davis, MD, Weill Cornell Medicine Editor's Choice Papers: What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

Proceedings from a symposium in partnership with NCOA and SCOS, featuring perspectives from Drs Michael Birrer and Ursula Matulonis on recent advances and real-world implications in gynecologic cancers. CME information and select publications

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.

Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology and Author of the editorial Featuring: David O'Malley, MD, The Ohio State University Editor's Choice Paper: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma Editorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data

When Shelley was diagnosed with uterine endometrial stage 4 cancer in January 2020, she knew as soon as she heard the word cancer, she'd go to Dana-Farber. She began chemotherapy treatments a month after her diagnosis until the cancer began growing again in November 2020. A few months later, Shelley started on a clinical trial that she has been on for the past six months. Her scans have shown no convincing evidence of metastatic disease. Shelley recalls the quality of care received by friends and family for multiple myeloma at Dana-Farber and has experienced the same high level of care herself. Shelley has also been a chiropractor for 20 years in East Hampton, Massachusetts. She also loves being outdoors through gardening, paddle boarding, mountain biking, and hiking. Last October, she climbed Mount Katahdin in Maine and hiked 100 miles of the Appalachian Trail from Georgia to North Carolina in April. She maintains a positive outlook and does not let cancer stop her from living her life.

Hour 3- Gresh and Keefe are joined by Shelley Wilton and the Wizard Dr. Ursula Matulonis, OK Eason and Dr. Reardon, as well as Bruins Head Coach Jim Montgomery for their third hour of the first day of the Jimmy Fund. Pat Harrington of Applebees makes a big donation

Featuring a discussion on the treatment of ovarian cancer with Dr Ursula Matulonis, moderated by Dr Neil Love.

Featuring perspectives from Dr Ursula Matulonis, including the following topics: Introduction: Journal Club with Ursula Matulonis, MD — Part 1 (0:00) Case: A woman in her late 60s with primary peritoneal carcinoma with a germline BRCA mutation who underwent naturopathic therapy — Dana M Chase, MD (31:08) Case: A woman in her late 70s with Stage IIIC fallopian tube cancer (homologous recombination proficient [HRp]) who underwent neoadjuvant chemotherapy — Paul DiSilvestro, MD (33:55) Case: A woman in her late 60s with high-grade serous ovarian carcinoma and extensive peritoneal and omental metastases (HRp) who received chemotherapy and bevacizumab followed by niraparib — Vikas Malhotra, MD (38:50) Case: A woman in her mid 70s with a germline BRCA1 mutation and bilateral breast cancer who experiences a complete response for 8 years to chemotherapy for metastatic ovarian cancer — Bruce Bank, MD (46:38) Faculty Survey (49:46) Journal Club with Dr Matulonis — Part 2 (54:02) Case: A woman in her mid 40s who experienced multiple relapses of microsatellite instability-high clear cell ovarian cancer — Syed F Zafar, MD (57:38) CME information and select publications

In this episode, we're featuring two conversations focusing on gynecologic oncology, both led by Dr. Ursula Matulonis, of Dana-Farber Cancer Institute. Dr. Matulonis, along with two colleagues, reviews data presented at the 2022 ASCO Annual Meeting in ovarian, primary peritoneal, and fallopian tube cancer.To listen to more podcasts from ASCO, visit asco.org/podcasts.

Today, Dr. Louis Meyers talks with Debbie Poland and Dr. Ursula Matulonis about Gynecologic Cancers. These include cancer of the cervix, uterus, and ovaries.

Karen was diagnosed with ovarian cancer in February 2019. She had experienced a gallbladder attack and then had a CT scan that uncovered an ovarian tumor.  In February 2020, Karen joined a new clinical trial for a new type of drug known as a bispecific antibody. The drug works by binding to two specific proteins that may be involved in the growth and survival of cancer.  Her doctor, Ursula Matulonis and other doctors at Dana-Farber worked hard to keep clinical trials like Karen's open during the pandemic when many other aspects of health care system were shutting down  See omnystudio.com/listener for privacy information.

A special audio program developed from a live webinar produced in conjunction with the 2020 AACR Virtual Annual Meeting. Featuring perspectives from Drs Maha Hussain, Ursula Matulonis, Philip A Philip and Hope S Rugo.

A special audio program developed from a live webinar produced in conjunction with the 2020 AACR Virtual Annual Meeting. Featuring perspectives from Drs Maha Hussain, Ursula Matulonis, Philip A Philip and Hope S Rugo.

Proceedings from the First Annual Miami General Medical Oncology Symposium — Module 6: Ovarian Cancer (OC) — Featuring moderated presentations of important clinical research and ongoing clinical trials by Drs Robert L Coleman and Ursula Matulonis. Moderated by Dr Neil Love. Presentation of General Medical Oncologist Practice Survey Results (00:00) Current and Future Role of PARP Inhibitors in the Treatment of OC — Dr Coleman (2:21) Other Recently Approved and Promising Investigational Strategies — Dr Matulonis (33:04) Boards Mini-Review: Role of Surgery in the Management of Recurrent OC; Secondary Debulking (47:41) Boards Mini-Review: Neoadjuvant versus Adjuvant Systemic Therapy for Primary OC, Including for Patients with BRCA Mutations (49:22) Select publications

Liza began suffering from bloating, fullness, and pelvic pain around July 2015. When she went to the doctor to get her discomfort checked out, Liza was diagnosed with Stage IIIC ovarian cancer.Liza's treatment has consisted of three weekly rounds of chemotherapy, surgery, and a clinical trial when her cancer reappeared in March 2016. Her treatment is ongoing and began just over two years ago.Despite her battle, Liza has been fortunate to have her family by her side. She is supported by her husband John, daughters, Cara and Peri, 25 and 20, and son, Johnny, 13. Liza speaks about how the nurses at Dana-Farber love when John comes with her to appointments!Liza works in marketing for Citizens Bank Wealth Management, but in her spare time, loves going to the Cape with her family, wandering the Museum of Fine Arts, walking through Audubon Parks, and exploring downtown Boston.Liza is incredibly grateful for her team at Dana-Faber, who have helped her and her family get through the hiccups that she has faced. They have made it easier for the family to live out a “new normal” life.Dr. Ursula Matulonis She can talk about the recent research in ovarian cancer and the importance of new combination therapies that have shown promising signs in treating ovarian cancer.Dr. Matulonis has led several clinical trials that have resulted in new drug approvals by the Food and Drug Administration for patients with ovarian cancer.

Hosted by: Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology and Author of the editorial Featuring: David O'Malley, MD, The Ohio State University Editor's Choice Paper: Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma Editorial: The rapid evolution of PARP inhibitor therapy for advanced ovarian cancer: Lessons being learned and new questions emerging from phase 3 trial long-term outcome data

Editor's Choice Papers:  What's in it for me?: A value assessment of gynecologic cancer clinical trials for Black women Editorial:  Achieving diversity in clinical trial enrollment by reducing burden and increasing value: A patient-centered approachHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic Oncology Featuring: Ann Oluloro, MD, MPH, University of WashingtonEloise Chapman-Davis, MD, Weill Cornell Medicine        

Editor’s Choice Paper: Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma Editorial:What's in your “lunchbox”? Sandwich versus sequential chemotherapy and irradiation for advanced endometrial cancerHosted by:Ursula Matulonis, MD, Associate Editor of Gynecologic OncologyFeaturing:Joyce Barlin, MD, Women’s Cancer Care Associates & Albany Medical CollegeGretchen Glaser, MD, Mayo Clinic John Weroha, MD, Mayo Clinic